1. Home
  2. MXCT vs NCO Comparison

MXCT vs NCO Comparison

Compare MXCT & NCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$1.38

Market Cap

155.8M

Sector

Health Care

ML Signal

SELL

NCO

Southern Cross Acquisition I Corp. Ordinary Shares

N/A

Current Price

$10.00

Market Cap

146.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MXCT
NCO
Founded
1999
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.8M
146.9M
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
MXCT
NCO
Price
$1.38
$10.00
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $4.11
N/A
AVG Volume (30 Days)
★ 1.4M
18.2K
Earning Date
11-10-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ 2.89
Revenue
★ $33,026,000.00
N/A
Revenue This Year
$4.77
N/A
Revenue Next Year
$10.06
N/A
P/E Ratio
★ N/A
$3.45
Revenue Growth
N/A
★ N/A
52 Week Low
$0.64
$9.83
52 Week High
$1.80
$9.98

Technical Indicators

Market Signals
Indicator
MXCT
NCO
Relative Strength Index (RSI) 55.07 73.71
Support Level $1.02 $9.90
Resistance Level $1.54 N/A
Average True Range (ATR) 0.14 0.01
MACD -0.01 0.00
Stochastic Oscillator 70.41 100.00

Price Performance

Historical Comparison
MXCT
NCO

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About NCO Southern Cross Acquisition I Corp. Ordinary Shares

Southern Cross Acquisition I Corp is a blank check company formed for the purpose of effecting into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

Share on Social Networks: